



DEEP-2 STUDY NEWSLETTER ISSUE 31 – JANUARY 2018

Dear DEEP-2 Investigators and CRAs, the database will be definitely locked on 31 January 2018.

Closure of e-CRF database

The Trial Management Team kindly inform you that the **closure of the DEEP-2 e-CRF database** has been scheduled on **31 January 2018**. From that moment on, it will not be possible to insert or modify any data. An official communication has been sent to all Investigators on 23 January 2018.

Therefore, in order to properly close down the e-CRF database and to fulfil the GCP requirements, all Investigators are kindly invited to be compliant with this deadline:

- completing and validating all the **e-CRF sections** that are still empty or in entry process;
- verifying that all **SAEs** have been recorded in the Adverse Event log of the e-CRF;
- solving all the pending queries arisen by the CRAs.

DEEP-2 Investigator Meeting

We are happy to announce that ApoPharma has organized the DEEP-2 Investigator Meeting that will be held in Milan (Italy) on 28 February - 1 March 2018.









This project has received funding from the European's Union's Seventh Framework Programme for research, technological development and demonstration under Grant Agreement n° 261483

DEEP-2 STUDY NEWSLETTER ISSUE 31 – JANUARY 2018

e-CRF Form Review Status at different centres

The Trial Management Team wishes to remind Investigators to correctly complete and validate all data in the e-CRF sections to allow the CRAs appointed to each study center to perform the check during the monitoring visits.










This project has received funding from the European's Union's Seventh Framework Programme for research, technological development and demonstration under Grant Agreement n° 261483

DEEP-2 STUDY NEWSLETTER ISSUE 31 – JANUARY 2018

Patients' Status



Site ID	PI	Planned	Randomized	Early termination	Completed	SAEs confirmed at COV
ITA/01	Maggio	10	11	0	11	0
EGY/02	El-Beshlawy	130	133	39	94	
GRE/03	Kattamis	12	11	3	00	10
ALB/04	Kreka	20	27	2	25	
CYP/05	Christou	12	8	7	1	
ITA/06	Filosa	14	14	4	10	7
TUN/07	Bejaoui	30	56	2	54	
ITA/08	Putti	9	9	1	8	7
ITA/09	Del Vecchio	12	6	0	6	0
ITA/10	Cuccia	4	3	3	0	0
ITA/11	Bisconte	4	1	0	1	0
ITA/12	Commendatore	6	1	0	1	1
ITA/14	Cosmi	5	5	1	4	3
ITA/15	Origa	7	5	2	3	3
ITA/16	Casini	4	3	0	3	0
ITA/17	Caruso	6	2	0	2	
UK/18	Telfer	20	19	1	18	12
UK/19	Grant	5	4	0	4	0
UK/20	Harewood	5	0	0	0	
EGY/23	Metwally Sherief	40	40	3	37	
EGY/24	Hassab	25	23	9	14	
ALB/31	Zaka	12	12	0	12	
TOTAL		392	393	77	316	43

COVs' Status					
Performed on 12/12/2017					
To be planned					
Performed on 18/10/2017					
To be planned					
To be planned					
Performed on 4-5/12/2017					
To be planned					
Performed on 6/11/2017					
Performed on 23/11/2017					
Performed on 11/12/2017					
Performed on 18/12/2017					
Performed on 1/12/2017					
Performed on 16/11/2017					
Performed on 29-30/11/2017					
Performed on 2/8/2017					
To be planned					
Performed on 15-16/1/2018					
Performed on 11/1/2018					
To be planned					
To be planned					
To be planned					
To be planned					





This project has received funding from the European's Union's Seventh Framework Programme for research, technological development and demonstration under Grant Agreement n° 261483

DEEP-2 STUDY NEWSLETTER ISSUE 31 – JANUARY 2018

FAQ

What if I cannot validate a form and the data seems correctly entered?

In case you are not able to validate a form even though all data have been correctly entered, please contact the Data Manager to the email trial.assistant@cvbf.net; you will be helped to validate the form.

Study Contacts

Please find below all DEEP-2 contacts that are glad to support you for any information that you may need:

Trial Leader:

Donato Bonifazi - pmdeep2@cvbf.net

Trial Coordinating Investigator:

Aurelio Maggio - md.amaggio@gmail.com

Trial Management Team:

» Clinical Research Coordinator:

Gabriele Morselli - gmorselli@cvbf.net

- » Data Manager: Paola Gandini trial.assistant@cvbf.net
- » Drug and Technical Operations Managers:

Bianca Tempesta - drugmanagement@deep-project.net

Valeria Pignataro - drugmanagement@cvbf.net

» Administrative Manager:

Marina Montanaro - mmontanaro@cvbf.net

Regulatory Submission Manager and Clinical Trial Archivist:

Elisa Cattani - ecattani@cvbf.net

Pharmacovigilance:

- » Safety Contact: Cristina Manfredi pharmacovigilance@deep-project.net
- » Qualified Person for Pharmacovigilance:

Mariagrazia Felisi - mariagraziafelisi@cvbf.net

Ferritin Evalutation Centers:

» Cristina Passarello - c.passarello@campuscutino.it

AORC Villa Sofia - Cervello, U.O.C. di Ematologia delle Malattie Rare del Sangue e degli Organi Emopoietici -Via Trabucco, 180 - 90146 Palermo, Italy

Ph.: +39 091 680 2770

» George S. Gorgy - gsgorgy@gmail.com

Egyptian Company For Biological Sciences (ECBS), 4 Kassem street, off Dokki street, Dokki, Giza, Egypt

Ph.: +2 02 33377593 - 333 84 684

Fax: +2 33377578 - 333 84 679

MRI Centre:

Resonance Health LTD - Help Desk

support@ferriscan.com

Postal Address: PO Box 1135 Nedlands, Western

Australia, 6909 Australia

Courier Address: 278 Stirling Highway, Claremont,

Western Australia, 6010 Australia

Ph.: +61 08 9285 300